Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

New genomic landscapes and therapeutic targets for biliary tract cancers

Michele Simbolo1, Matteo Fassan2, Andrea Mafficini3

  • 1ARC-Net Research Centre, University and Hospital Trust of Verona, Piazzale L. Scuro 2, 37134 Verona, Italy.

Frontiers in Bioscience (Landmark Edition)
|December 29, 2015
PubMed

Insights

Biliary tract cancers (BTCs) have distinct molecular profiles, with intrahepatic types showing IDH1/2 and BAP1 alterations, and others featuring KRAS and TP53 mutations. This molecular understanding is key for developing targeted therapies.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Research

Background:

  • Biliary tract cancers (BTCs) represent a heterogeneous group of neoplasms with poor prognoses.
  • Currently, no targeted molecular agents are approved for BTC treatment, highlighting a significant unmet need.
  • The molecular landscape of BTCs has only recently begun to be elucidated.

Purpose of the Study:

  • To investigate the molecular alterations in different subtypes of biliary tract cancers.
  • To identify potential therapeutic targets and biomarkers for personalized medicine in BTCs.

Main Methods:

  • Comprehensive mutational profiling of BTCs.
  • Targeted next-generation sequencing (NGS) to uncover genetic alterations.
  • Analysis of key cellular pathways involved in BTC development.

Main Results:

  • Intrahepatic cholangiocarcinomas are characterized by IDH1/2 and BAP1 alterations.
  • Extrahepatic cholangiocarcinomas and gallbladder carcinomas frequently exhibit KRAS and TP53 alterations.
  • Identified alterations in cell cycle regulators, chromatin remodeling, mTOR, TGF-beta/Smad, and receptor tyrosine kinase signaling pathways.

Conclusions:

  • BTCs exhibit distinct molecular signatures that vary by subtype.
  • Understanding these molecular alterations is crucial for developing novel targeted therapies.
  • Correlation with clinical trials is necessary to identify predictive biomarkers for personalized BTC treatment.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109